Loading

Archives of Emergency Medicine and Critical Care

Comparison of Intranasal Ketamine Spray and Intravenous Morphine in Reducing Headache among Patients with Headache

Research Article | Open Access

  • 1. Department of Emergency Medicine, Shahid Sadoughi University of Medical Sciences, Iran
  • 2. Medical doctor, Shahid Sadoughi University of Medical Sciences, Iran
  • 3. Department of Emergency Medicine, Samen al-hojaj hospital, Sirjan University of Medical Sciences and Health services, Iran
+ Show More - Show Less
Corresponding Authors
Abbas Meidany, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, Tel: 989162618191
Abstract

Background & Aim: Primary headaches are a common presentation in emergency departments, and the current standard treatments involve the use of NSAIDs and opioids. However, there is growing interest in exploring alternative therapies, such as ketamine, for pain management in headache patients. This study aimed to compare the efficacy of intranasal ketamine with intravenous morphine in patients with acute headache, considering the rapid and painless administration route of intranasal ketamine.

Materials and Methods: This double-blind clinical trial was conducted on patients with acute headache who were referred to the emergency departments of Shahid Sadougi and Rahnamon Hospitals in Yazd between 2019 and 2021. Using Simple Random Sampling, patients were divided into two groups: the case group, which received intranasal ketamine, and the control group, which received intravenous morphine. Pain intensity, assessed using the Visual Analogue Scale (VAS), along with side effects, treatment response, need for additional doses, pain relief, treatment failure, SERSDA (Side effects rating scale for dissociative anesthetics), and onset of drug effect were measured and recorded at various time intervals (0, 5, 10, 15, 30, and 60 minutes). Data analysis was performed using the SPSS software.

Results: A total of 100 patients with acute headache participated in the study, with half receiving intranasal ketamine and the other half receiving intravenous morphine. After 60 minutes of treatment, the average pain score in the morphine group was 1.95 ± 0.35, while in the ketamine group, it was 1.47 ± 0.34. The ketamine group showed a treatment response (4.73 ± 0.61) within 5 minutes of starting the treatment, whereas the morphine group exhibited a response (4.25 ± 0.52) after 15 minutes. The most common side effects in the morphine group were nausea, dizziness, and hypotension, while burning and irritation of the nasal mucosa, nausea, lightheadedness, and hallucinations were the most common side effects in the ketamine group.

Conclusion: Based on the findings of this study, intranasal ketamine demonstrated similar analgesic efficacy to intravenous morphine in the management of acute headaches (after ruling out secondary causes). Moreover, intranasal ketamine exhibited a faster onset of action compared to intravenous morphine. Therefore, intranasal ketamine may be considered a suitable alternative to intravenous morphine for pain management in patients with acute headaches.

Keywords

• Intranasal Ketamine

• Intravenous

• Morphine

• Headache

• Patients

CITATION

Abarghouei SA, Roknabadi ZR, Jafari M, Meidany A (2023) Comparison of Intranasal Ketamine Spray and Intravenous Morphine in Reducing Headache among Patients with Headache. Arch Emerg Med Crit Care 7(2): 1058.

ABBREVIATIONS

SERSDA: Side Effects Rating Scale for Dissociative Anesthetics; VAS: Visual Analogue Scale

INTRODUCTION

Headache is one of the most common complaints among patients visiting the emergency department [1], and is even more prevalent than the common cold [2]. Approximately half of all adults experience a headache at least once a year [3]. Headaches are categorized as either primary or secondary. Primary headaches cause significant daily pain and disability but are not physiologically dangerous. On the other hand, secondary headaches may indicate underlying pathology. The presence of Red Flags assists doctors in diagnosing secondary headaches [4]. Examples of secondary headaches include meningitis, intracranial hemorrhages, subarachnoid hemorrhage, aneurysm rupture, arteriovenous malformation, intraparenchymal hemorrhage, temporal arthritis, acute angle-closure glaucoma, seizures, digestive disorders, brain tumors, hypertension, dental infections, allergies, and overuse of painkillers [5].

Migraine, recognized by the World Health Organization as one of the top 20 debilitating diseases worldwide [2], is a type of primary headache. The direct cost associated with this disease is estimated at one billion dollars per year. Cluster headaches and tension headaches are also common types of primary headaches that frequently lead patients to seek care in emergency departments and other medical centers [6]. However, there are over 200 types of headaches, ranging from harmless to life-threatening [7]. Most cases of headaches are benign and only require symptomatic treatment. Therefore, headaches are considered symptoms rather than diseases. In severe and intolerable cases, they may indicate an underlying condition, and individuals with chronic headaches are at an increased risk of developing depression, according to psychiatrists [3].

Currently, nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids, such as morphine, are commonly used for headache treatment in the emergency department after ruling out lifethreatening causes. Morphine, an opioid widely used for acute headache attacks, takes one to six minutes to take effect when administered intravenously, with peak effect occurring after 20 minutes. Its half-life is approximately two to three hours. Due to side effects such as nausea, vomiting (especially during initial use), constipation, drowsiness, hypotension, orthostatic hypotension, apnea, respiratory suppression, dry mouth, sweating, facial flushing, dizziness, decreased heart rate, decreased body temperature, hallucinations, mood changes, dependence, addiction, and cognitive impairment, physicians aim to minimize its usage [8].

Ketamine is a central nervous system depressant with various applications in anesthesia [9]. Compared to other anesthetic drugs, ketamine is considered less hazardous because it does not depress the respiratory center or impair blood circulation, nor does it suppress the gag reflex [10]. When administered intravenously, ketamine takes effect within 5-10 minutes, with a half-life of approximately two to three hours [11,12].

Nasal administration of medication is a painless method that provides rapid pain relief with minimal delay. From a pharmacokinetic perspective, the nasal mucosa, rich in blood vessels, facilitates rapid drug absorption with minimal side effects [13,14]. In recent years, numerous studies have investigated the effects of ketamine in the form of nasal spray, intravenous injection, rectal administration, and even topical application for reducing various types of pain, including renal colic, with positive effects reported [15].

Given the significance of pain management in patients presenting to the emergency department and the limited studies comparing the analgesic effects of intranasal ketamine spray and intravenous morphine in acute headache patients, this clinical trial aimed to assess and compare the efficacy of intranasal ketamine spray and intravenous morphine in reducing headache severity among patients attending the emergency departments of Shahid Sadougi and Rahnamon Hospitals in Yazd between 2019 and 2021.

MATERIALS AND METHODS

Design & setting

This study is a double-blind randomized controlled clinical trial that was conducted on 100 Patients with acute headache, older than 14 years and younger than 65 years old, who referred to the emergency departments of Shahid Sadougi and Rahnamon Hospitals in Yazd during 2019-2021.

This study was reviewed and approved by the ethics committee of Shahid Sadouqi University of Yazd (ethics code: IR.SSU.MEDICINE.REC.1400.188) and before the research, the objectives of the study were explained to the patients and if they want to participate in the study, a written consent was obtained from them.

If the patient was unable to give written consent due to reasons such as language difference or inability to write, consent was obtained from the patient’s legal guardian, and the authors fully adhered to the Declaration of Helsinki Principles during the study.

Sample

Size With an alpha error rate of 5% and a power of 80%, and taking into account the standard deviation of 5.3 to reach a significant difference of 2 units in the average VAS score, the number of 50 people was determined. 55 people in each group and a total of 110 people were considered with a 10% drop (if there is no drop, 100 people). After explaining the goals of the project to the patients and obtaining written consent from them, the patients were entered into one of the intervention and control groups by Simple Random Sampling.

Procedure and Intervention

The inclusion criteria for this study were older than 14 years and younger than 65 years, all headaches referred to the emergency department including migraine, cluster and tension with a pain score greater than or equal to four.

Patients with consciousness level less than 15, symptoms of increased ICP, symptoms of nerve lateralization, O2 saturation less than 90%, suspected of subarachnoid hemorrhage (SAH), fever and Neck stiffness, history of psychosis, known liver and kidney disease, taking painkillers in the last 4 hours, eye complications (symptoms of increased IOP, eye pain, blurred vision and eye redness), pregnancy and breastfeeding, nasal congestion, drug addiction, systolic blood pressure less than 90 and more than 180, respiratory rate less than 10, pulse rate less than 60 and more than 140, history of allergy to any of the drugs used in the study, brain tumor and not consenting to participate in the project were excluded from this study.

100 patients who met the conditions for entering the study, after obtaining informed consent from the patient or legal guardian and explaining the process of this study and performing Primary Care, as well as after rolling out secondary headaches, they were evaluated for the absence of nasal septum deviation and other structural disorders of the nose and then they were divided into group A (case group) and B (control group) by Simple Random Sampling (Figure 1).

CONSORT flowchart of study patients

Figure 1: CONSORT flowchart of study patients.

In group A, 50 patients who were treated with intranasal ketamine at a dose of 0.7 mg/kg (the maximum dose was considered 40 mg) in the form of three puffs inside each nostril (each puff containing 7 mg of ketamine) and 10 cc of normal intravenous saline were injected slowly.

In group B, 50 patients were treated with placebo nasal spray and 0.1 mg/kg intravenous morphine (the maximum dose was considered 5 mg) were injected slowly which was diluted with 10 cc of normal intravenous saline.

How to make ketamine nasal spray: In this study, ketamine vials manufactured by Sterop company were used. Each 10 cc vial contained 500 mg of ketamine and 50 mg of benzalkonium chloride (as a preservative). Desmopressin nasal sprays of Raha Company with a volume of 10 cc were emptied and sterilized, then prepared solution was poured into it. Each spray puff contained 7 mg of ketamine and the sprays could be used up to one month after opening the vial.

How to make the placebo spray: 10 cc vials of distilled water made by SunLife Company were used to make the placebo spray. 50 mg of benzalkonium chloride (as a preservative) made by Behsa company was dissolved in 10 cc vials of distilled water. Desmopressin nasal sprays of Raha Company with a volume of 10 cc were emptied and sterilized, then prepared solution was poured into it and the sprays could be used up to one month after opening the vial.

All the drugs were unlabeled. Neither the research doctor nor the patient knew the type of drug prescribed (double blind). When the patients entered the study, the necessary demographic information was collected based on the prepared checklists. The clinical symptoms of the patients were evaluated by the research doctor, and then the drugs were injected and used by the nurse. The clinical symptoms of the patients, pain intensity and possible side effects of the drugs (Nausea and vomiting, hot flushing, irritation and burning of nasal mucosa, systolic blood pressure less than 90 or more than 180, hallucination and agitation) were investigated by the research doctor at 0, 5, 10, 15, 30, and 60 minutes after drug administration. Also, side effect rating scale for dissociative anesthetics (SERSDA) was used to measure the effects of ketamine identity disorder (dissociative).

In this study, response to treatment was considered a reduction of at least two pain scores based on the patient’s VAS criteria after receiving the first or second dose, and painlessness was considered as a pain score based on VAS criteria of less than four.

If there is no reduction of 2 scores of pain intensity according to the VAS criterion, after 15 minutes, the second dose was prescribed in the amount of half of the initial dose. If after 30 minutes of receiving the first dose (after 15 minutes of receiving the Second dose), the patient’s pain was not improving and also if drug side effects occur, was considered the failure of the treatment and was used the rescue drug. The rescue drug was 30 mg of intravenous ketorolac.

Demographic information was collected from the patients through interviews and recorded in the prepared checklists. Patients’ pain was evaluated based on VAS. The Visual Analogue Scale (VAS) index is a 10 cm horizontal bar that shows the patient’s pain status on the axis from zero to ten [16] (Figure 2).

Assessment of pain intensity based on VAS

Figure 2: Assessment of pain intensity based on VAS.

The Side Effects Rating Scale for Dissociative Anesthetics (SERSDA) was employed to evaluate the side effects of ketamine. This nine-component scale assesses the severity of each component from “0” (no side effects) to “4” (very bothersome). The components include fatigue, headaches, dizziness, feelings of unreality, generalized discomfort, changes in hearing, changes in mood, hallucinations, and changes in vision. Although not validated, SERSDA was chosen as it is regularly used in studies of ketamine’s side effects and provides a comprehensive overview of the drug’s potential adverse effects [17] (Figure 3).

Side effects rating scale for dissociative anesthetics (SERSDA) (18)

Figure 3: Side effects rating scale for dissociative anesthetics (SERSDA) (18).

Statistical Analysis

The data was analyzed using SPSS version 26 statistical software and with the help of The Paired-Samples T Test, Independent-Sample, Mann-Whitney U Test, Chi-Square Sample and ANOVA statistical tests and all P-value values less than 0.05 were considered statistically significant.

Primary and Secondary

Outcomes Primary outcome, the time to start responding to treatment and secondary outcome, the time to reach painlessness and the rate of complications in both groups was considered.

RESULTS

This study included a total of 100 patients with acute headache who were divided into two groups: intranasal ketamine (n=50) and intravenous morphine (n=50). Of the patients, 52% (52 individuals) were male and 48% (48 individuals) were female. The mean age of the patients was 36.53 ± 12.73 years. The two groups were comparable in terms of age (p-value = 0.76) and gender (p-value = 0.54), showing no significant differences (Table 1).

Table 1: Baseline Characteristics

Variable

Ketamine (n = 50)

Morphine (n = 50)

Age, mean (SD), y

35.83(12.87)

37.23(13.32)

Male  No. (%)

24(48)

28(56)

Female  No. (%)

26(52)

22(44)

Response to treatment  No. (%)

48(96)

46(92)

Treatment failure  No. (%)

2(4)

4(8)

Baseline VAS score, mean (SD), mm

6.89(0.72)

6.78(0.68)

Table 2 presents the results of the study. The average pain score of patients treated with morphine prior to treatment initiation was 6.78 ± 0.68, which significantly reduced to 1.95 ± 0.35 sixty minutes after intravenous morphine administration. In the group treated with intranasal ketamine, the initial pain score was 6.89 ± 0.72, which decreased to 1.47 ± 0.34 sixty minutes after treatment initiation.

The group treated with intranasal ketamine exhibited a response to treatment (4.73 ± 0.61) within five minutes of treatment initiation, reaching a pain-free state (3.15 ± 0.57) after ten minutes. On the other hand, the group treated with morphine responded to treatment (4.25 ± 0.52) after fifteen minutes, achieving a pain-free state (3.39 ± 0.43) after thirty minutes (Table 2). Based on the study results, 92% (46 patients) in the morphine group and 96% (48 patients) in the ketamine group achieved pain relief.

Table 2: Pain score (VAS) at 5, 10, 15, 30 and 60 Minutes

Time After Study Medication

mean (SD), mm

5 min

 

Ketamine

4.73(0.61)*

Morphine

5.61(0.71)

10 min

 

Ketamine

3.15(0.57)**

Morphine

4.98(0.67)

15 min

 

Ketamine

2.26(0.45)

Morphine

4.25(0.52)*

30 min

 

Ketamine

1.78(0.45)

Morphine

3.39(0.43) **

60 min

 

Ketamine

1.47(0.34)

Morphine

1.95(0.35)

*Response to treatment

**painlessness

 

According to Table 1, 8% (4 individuals) of the patients treated with intravenous morphine and 4% (2 individuals) of the patients treated with intranasal ketamine did not respond to the treatment. The Chi-square test indicated no significant difference in treatment success between the two study groups (p-value = 0.14). Additionally, 20% (10 patients) in the morphine group and 32% (16 patients) in the ketamine group required a second dose.

Table 3 displays the occurrence of complications. Among the patients treated with morphine, 42% (21 patients) experienced complications, with nausea being the most common (10%). In the ketamine group, 50% (25 patients) experienced complications, with burning and irritation of the nasal mucosa being the most frequent (18%). Furthermore, 30% (15 patients) in the ketamine group exhibited side effects that met the criteria of the Side Effects Rating Scale for Dissociative Anesthetics (SERSDA) (Table 3). Except for SERSDA, there were no significant differences in the incidence of drug side effects between the two medications (p-value = 0.033).

Table 3: Complications

Variable

No. (%)

 

Ketamine (n = 50)

Morphine (n = 50)

Nausea

4(8)

5(10)

Vomiting

1(2)

2(4)

Dizziness

0(0)

3(6)

Hypotension

0(0)

3(6)

Hypertension

1(2)

0(0)

hot flashes

0(0)

1(2)

Lightheadedness

4(8)

4(8)

Delusion

5(10)

0(0)

Decrease in blood oxygen saturation

1(2)

1(2)

Decreased respiratory rate

0(0)

2(4)

Agitation

0(0)

0(0)

Irritation of the nasal mucosa

9(18)

0(0)

SERSDA

15(30)

0(0)

DISCUSSION

The findings of our study demonstrate that intranasal ketamine treatment elicits a faster response compared to intravenous morphine, resulting in a shorter time to achieve pain relief. However, the changes in pain scores within 60 minutes after treatment initiation indicate that intranasal ketamine and intravenous morphine exhibit similar efficacy in alleviating headaches. Furthermore, the incidence of drug side effects, excluding SERSDA, is comparable between the two treatment groups. Common side effects observed in patients treated with morphine include nausea, dizziness, and hypotension, while patients treated with intranasal ketamine experienced burning and irritation of the nasal mucosa, nausea, lightheadedness, and hallucinations. Additionally, the assessment of identity disorder indicators (SERSDA) in patients treated with intranasal ketamine indicates the safety of ketamine in this regard. This lack of occurrence of identity disorder can be attributed to the dosage of ketamine used and the intranasal route of drug administration.

A study conducted by Abbasi et al., in 2018 examined the comparison between the combined effect of intravenous morphine and ketamine and intravenous morphine alone in patients presenting with renal colic in the emergency department.Consistent with our study, this research demonstrated that the combination of intravenous morphine and ketamine resulted in significantly higher speed and effectiveness compared to intravenous morphine alone. The side effects of ketamine in this study, similar to ours, included O2 saturation below 90%, nausea, vomiting, and nystagmus. Notably, nausea and vomiting were the most common side effects observed in both the intravenous morphine and ketamine combination treatment group [19]. Although nystagmus is a common side effect of ketamine, its reversibility and benign nature were not investigated in our study.

In another study by Shrestha et al., in 2016, which aligns with our findings, the effects of intranasal ketamine in managing acute pain in patients visiting the emergency department were investigated. Dizziness and mood changes were reported as the most common side effects of ketamine in this study [20]. Finally, the results of this research indicated that intranasal ketamine can be utilized as an effective analgesic in the emergency department.

Stacy Reynolds et al., conducted a study in South Carolina in 2017 comparing the effects of intranasal ketamine with intranasal fentanyl on 80 children with limb fractures. The most common side effect observed with ketamine was a bad taste (90%), followed by dizziness (73%), drowsiness (46%), and nasal irritation (24%). The study concluded that intranasal ketamine can serve as an effective pain reliever for reducing pain in patients after orthopedic procedures (21), which is consistent with our study. However, the investigation of intranasal ketamine side effects in these two studies yielded different results, which could be attributed to variations in sample size and age range among the studied patients.

According to our study results, the average pain score in patients treated with intranasal ketamine was 6.89 out of 10, which decreased to 1.47 after 60 minutes. Only 2 patients (4%) from the ketamine group did not respond to the treatment. In a 2010 study by Krusz et al., the effects of intravenous ketamine on headache and pain disorders in 247 patients were investigated. The results showed an average reduction of 5 points on the pain scale after treatment with intravenous ketamine. Of the patients, 151 received two doses, 90 received three doses, and 6 patients did not respond to the treatment despite receiving three doses of the drug [22]. This reduction in response rate compared to our study can be attributed to the difference in sample size. Overall, both studies yielded similar results, highlighting the speed and efficacy of ketamine in reducing and alleviating headaches.

LIMITATIONS

One of the main limitations of our study was the short followup period for patients. Evaluating the effectiveness of the drug over longer follow-up periods is recommended for future studies. Another limitation was the absence of a placebo group, as ethical considerations prevented following patients without medical intervention. It is advisable to explore alternative routes of drug administration (such as intramuscular and local) and different administration regimens (continuous and infusion) in future studies.

CONCLUSION

Based on the results of our study, intranasal ketamine significantly alleviates headaches in patients with acute primary headache (after ruling out secondary causes). Compared to intravenous morphine, intranasal ketamine exhibits similar effectiveness in reducing patients’ pain scores according to the Visual Analog Scale (VAS) criteria, without inducing a higher incidence of side effects. Nausea, dizziness, and hypotension were the most common side effects of intravenous morphine, while burning and irritation of nasal mucosa, hallucinations, nausea, and lightheadedness were the most common side effects of intranasal ketamine.

ACKNOWLEDGEMENTS

The authors appreciate the insightful cooperation of Medical Sciences and the staff of the Emergency Departments of Shahid Sadougi and Rahnamon Hospital, Yazd, Iran.

REFERENCES

1. Rasmussen BK. Migraine and tension-type headache are separate disorders. Cephalalgia. 1996; 16: 217-219.

2. Rasmussen BK. Epidemiology of headache. Cephalalgia. 1995; 15: 44- 67.

3. Wei DYT, Ong JJY, Goadsby PJ. Cluster headache: epidemiology, pathophysiology, clinical features, and diagnosis. Ann Indian Acad Neurol. 2018; 21: S3.

4. Goadsby PJ, Evers S. International classification of headache disorders-ICHD-4 alpha. Cephalalgia. SAGE Publications Sage UK: London, England; 2020; 40: 887-888.

5. Goadsby PJ, Raskin NH. Chapter 14. Headache. Harrison’s Princ Intern Med 18e New York, NY McGraw-Hill. 2012.

6. Akpek S, Arac M, Atilla S, Önal B, Yücel C, Isik S. Cost?effectiveness of computed tomography in the evaluation of patients with headache. Headache J Head Face Pain. 1995; 35: 228-230.

7. Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020; 40: 1026-1044.

8. Gan TJ, Ginsberg B, Glass PSA, Fortney J, Jhaveri R, Perno R. Opioidsparing effects of a low-dose infusion of naloxone in patientadministered morphine sulfate. J Am Soc Anesthesiol. 1997; 87: 1075-1081.

9. Abdollahpour A, Saffarieh E, Zoroufchi BH. A review on the recent application of ketamine in management of anesthesia, pain, and health care. J Fam Med Prim Care. 2020; 9: 1317.

10. Tandon M, Pandey VK, Dubey GK, Pandey CK, Wadhwa N. Addition of sub-anaesthetic dose of ketamine reduces gag reflex during propofol based sedation for upper gastrointestinal endoscopy: a prospective randomised double-blind study. Indian J Anaesth. 2014; 58: 436.

11. Pal HR, Berry N, Kumar R, Ray R. Ketamine dependence. Anaesth Intensive Care. 2002; 30: 382-384.

12. Wieber J, Gugler R, Hengstmann JH, Dengler HJ. Pharmacokinetics of ketamine in man. Anaesthesist. 1975; 24: 260-263.

13. Hussain AA. Intranasal drug delivery. Adv Drug Deliv Rev. 1998; 29: 39-49. 14. Pires A, Fortuna A, Alves G, Falcão A. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci. 2009; 12: 288-311.

15. Lapidus KAB, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014; 76: 970-976.

16. Azizkhani R, Akhbari K, Masoumi B, Parna A, Golshani K. Comparison of Efficacy of Nebulized Ketamine with Morphine and Intravenous Morphine in Pain Reduction in Patients with Traumatic Long?Bone Fractures Admitted to Emergency Department. Arch Trauma Res. 2018; 7: 114-120.

17. Clattenburg EJ, Hailozian C, Haro D, Yoo T, Flores S, Louie D, et al. Slow Infusion of Low?dose Ketamine Reduces Bothersome Side Effects Compared to Intravenous Push: A Double?blind, Double? dummy, Randomized Controlled Trial. Acad Emerg Med. 2018; 25: 1048-1052.

18. Miller JP, Schauer SG, Ganem VJ, Bebarta VS. Low-dose ketamine vs morphine for acute pain in the ED: a randomized controlled trial. Am J Emerg Med. 2015; 33: 402-408.

19. Abbasi S, Bidi N, Mahshidfar B, Hafezimoghadam P, Rezai M, Mofidi M, et al. Can low-dose of ketamine reduce the need for morphine in renal colic? A double-blind randomized clinical trial. Am J Emerg Med. 2018; 36: 376-379.

20. Shrestha R, Pant S, Shrestha A, Batajoo KH, Thapa R, Vaidya S. Intranasal ketamine for the treatment of patients with acute pain in the emergency department. World J Emerg Med. 2016; 7: 19.

21. Reynolds SL, Bryant KK, Studnek JR, Hogg M, Dunn C, Templin MA, et al. Randomized controlled feasibility trial of intranasal ketamine compared to intranasal fentanyl for analgesia in children with suspected extremity fractures. Acad Emerg Med. 2017; 24: 1430- 1440.

22. Krusz J, Cagle J, Scott-Krusz V. IV ketamine treatment for multiple headache and pain disorders. J Pain. 2010; 11: S43.

Abarghouei SA, Roknabadi ZR, Jafari M, Meidany A (2023) Comparison of Intranasal Ketamine Spray and Intravenous Morphine in Reducing Headache among Patients with Headache. Arch Emerg Med Crit Care 7(2): 1058.

Received : 22 Sep 2023
Accepted : 22 Oct 2023
Published : 30 Oct 2023
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X